下瀬先生が共著者であり、kurume Liver Cancer Study Groupを含めた国際共同研究が Liver Int に掲載されました
【原著】
査読有
doi：10.1111/liv.14817
PubMed No.：33547848
ISSN：1478-3223
2019 Impact Factor：5.175
あ
誌名：Liver international（Liver Int）
査読有
doi：10.1111/liv.14817
PubMed No.：33547848
ISSN：1478-3223
2019 Impact Factor：5.175
あ
誌名：Liver international（Liver Int）
発行年月：2021年2月
巻号頁：inpress 2021
あ
論題：Lenvatinib versus Sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis
著者：Andrea Casadei-Gardini, Mario Scartozzi, Toshifumi Tada, Changhoon Yoo, Shigeo Shimose, Gianluca Masi, Sara Lonardi, Giovanni Luca Frassineti, Silvestris Nicola, Fabio Piscaglia, Takashi Kumada, Kim Hyung-Don, Hironori Koga, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Yeonghak Bang, Masanori Atsukawa, Takuji Torimura, Kunihiko Tsuj, Ei Itobayashi, Hidenori Toyoda, Shinya Fukunishi, Lorenza Rimassa, Margherita Rimini, Stefano Cascinu, Alessandro Cucchetti
巻号頁：inpress 2021
あ
論題：Lenvatinib versus Sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis
著者：Andrea Casadei-Gardini, Mario Scartozzi, Toshifumi Tada, Changhoon Yoo, Shigeo Shimose, Gianluca Masi, Sara Lonardi, Giovanni Luca Frassineti, Silvestris Nicola, Fabio Piscaglia, Takashi Kumada, Kim Hyung-Don, Hironori Koga, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Yeonghak Bang, Masanori Atsukawa, Takuji Torimura, Kunihiko Tsuj, Ei Itobayashi, Hidenori Toyoda, Shinya Fukunishi, Lorenza Rimassa, Margherita Rimini, Stefano Cascinu, Alessandro Cucchetti
あ
あ
